ELIEM THERAPEUTICS
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. Eliem Therapeutics develops and commercializes potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
ELIEM THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Redmond, Washington, United States
Country:
United States
Website Url:
http://www.eliemtx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
171.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
LifeArc
LifeArc investment in Series B - Eliem Therapeutics
Access Biotechnology
Access Biotechnology investment in Series B - Eliem Therapeutics
Intermediate Capital Group
Intermediate Capital Group investment in Series B - Eliem Therapeutics
Samlyn Capital
Samlyn Capital investment in Series B - Eliem Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Series B - Eliem Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Eliem Therapeutics
Access Biotechnology
Access Biotechnology investment in Series A - Eliem Therapeutics
Intermediate Capital Group
Intermediate Capital Group investment in Series A - Eliem Therapeutics
RA Capital Management
RA Capital Management investment in Series A - Eliem Therapeutics
RA Capital Management
RA Capital Management investment in Venture Round - Eliem Therapeutics
Official Site Inspections
http://www.eliemtx.com Semrush global rank: 6.95 M Semrush visits lastest month: 677
- Host name: 63.24.202.35.bc.googleusercontent.com
- IP address: 35.202.24.63
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Eliem Therapeutics"
Eliem Therapeutics Announces the Closing of its Acquisition of …
Jun 27, 2024 In that role, she led the organization from early-stage private company to a late-phase public company with internal GMP manufacturing capabilities, pioneering new …See details»
Eliem Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. …See details»
TENET ACQUISITION OVERVIEW - Eliem Therapeutics, Inc.
Apr 11, 2024 [email protected] or by telephone at (339) 970-2843. Participants in the Solicitation Eliem, Tenet and their respective directors and executive officers may be …See details»
Eliem Therapeutics Announces Agreement to Acquire Tenet …
Apr 11, 2024 Management and Organization. ... on Eliem’s website at www.eliemtx.com or by contacting Eliem’s Investor Relations via email at [email protected] or by …See details»
Eliem Therapeutics Company Profile - Office Locations ... - Craft
Oct 29, 2024 Eliem Therapeutics is a company developing therapeutics intended to treat neuronal excitability disorders. It offers specialized research and development of drugs for the …See details»
Eliem Therapeutics Announces Agreement to Acquire Tenet …
Apr 11, 2024 Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 …See details»
Eliem Therapeutics - Overview, News & Similar companies
Apr 10, 2024 www.eliemtx.com. Revenue $6.4 Million. Stock Symbol ELYM. Industry Pharmaceuticals Healthcare . Recent News & Media. WilmerHale Advises Eliem Therapeutics …See details»
Eliem Therapeutics Announces Additions to its Leadership Team
Aug 26, 2024 Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United …See details»
Eliem Therapeutics Announces the Closing of its Acquisition of …
Jun 27, 2024 In connection with the closing of the acquisition, Eliem is announcing additions to its executive leadership team with the appointment of Aoife Brennan, M.B., Ch.B., as …See details»
Eliem Therapeutics (ELYM) to Acquire Tenet Medicines, Announces ...
Apr 11, 2024 Investors and security holders may obtain free copies of these documents (when they become available) on the SEC’s website at www.sec.gov, on Eliem’s website at …See details»
Eliem Therapeutics Emerges from Stealth with $80 Million Invested …
Mar 25, 2021 /PRNewswire/ -- Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80...See details»
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial …
Assets : December 31, 2021 : December 31, 2020 : Current assets: Cash and cash equivalents $ 46,922 $ 20,487 : Short-term marketable securities : 89,558See details»
Eliem Therapeutics Announces the Closing of its Acquisition of …
Jun 27, 2024 Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune …See details»
Eliem Therapeutics Announces Agreement to Acquire Tenet
Apr 11, 2024 Management and Organization. Following the closing of the acquisition, the combined company’s leadership team will include members of Tenet’s current leadership …See details»
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial ...
Mar 6, 2023 Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline …See details»
ELYM Press Release: Eliem Therapeutics Announces Agreement to …
Apr 11, 2024 Management and Organization. Following the closing of the acquisition, the combined company's leadership team will include members of Tenet's current leadership …See details»
Release Details - Eliem Therapeutics, Inc.
Jan 18, 2022 ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 …See details»
Eliem Therapeutics Announces Agreement to Acquire Tenet …
Apr 11, 2024 Management and Organization. Following the closing of the acquisition, the combined company’s leadership team will include members of Tenet’s current leadership …See details»
Eliem Therapeutics Reports Second Quarter Financial Results
Sep 13, 2021 On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for …See details»
Eliem Therapeutics Provides Update on Pipeline Progress
Oct 5, 2022 Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram …See details»